Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 2,212 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now owns 19,386 shares in the company, valued at $3,073,262.58. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Natera Price Performance

Shares of NTRA traded down $5.05 during trading hours on Friday, hitting $146.06. 2,242,126 shares of the company were exchanged, compared to its average volume of 1,338,689. The company has a market capitalization of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. The firm has a fifty day simple moving average of $127.38 and a 200-day simple moving average of $115.46. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company's revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) earnings per share. As a group, sell-side analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. TD Cowen increased their price target on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research report on Wednesday. Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday. Morgan Stanley increased their price objective on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a report on Thursday. Stephens reissued an "overweight" rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Finally, StockNews.com lowered Natera from a "hold" rating to a "sell" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.65.

Institutional Trading of Natera

Hedge funds have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new stake in shares of Natera in the second quarter valued at $28,000. Quarry LP raised its holdings in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after buying an additional 190 shares in the last quarter. GAMMA Investing LLC raised its holdings in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after buying an additional 108 shares in the last quarter. Covestor Ltd grew its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Natera in the third quarter valued at about $57,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.